消息面上，和誉医药近日宣布，公司在2024年欧洲肿瘤学会（ESMO）年会上公布了其自主研发的小分子FGFR4抑制剂依帕戈替尼（ABSK011）在1期临床试验中针对FGF19过表达的晚期肝细胞癌的安全性和有效性的最新临床数据。值得一提的是，该研究还荣获本次ESMO大会的“最佳壁报奖”。

Immutep Limited (ASX:IMM) CEO and Executive Director Marc Voigt discusses the company's latest results in head and neck cancer.

例如，FGFR4抑制剂在这一领域已经显示出巨大的潜力。 2024年的ESMO大会上，FGFR4抑制剂依帕戈替尼（ABSK011）公布的数据显示： 其220mg BID组在经ICIs和mTKIs治疗的FGF19过表达肝细胞癌患者中，总体缓解率（ORR）达到44.8%，中位缓解持续时间（mDOR）为7.4个月，中位无 ...

ESMO Congress, CURE® spoke with an expert about Fotivda and certain challenges patients may experience, such as side effects.

NKT2152, a novel HIF2a inhibitor, demonstrates significant efficacy in patients with advanced clear cell renal cell carcinoma ...

Jacob E. Berchuck, MD, discusses research behind using a blood-based liquid biopsy over traditional PSMA PET scans presented ...

The European Society for Medical Oncology’s annual meeting this week featured the hottest emergent areas of cancer ...

Neoadjuvant therapy is an essential part of high-risk stage III resectable melanoma management, with combination ...

Research presented at ESMO 2024 could have practice-changing implications for breast, gastrointestinal, genitourinary, and gynecologic cancers.

9月13~17日，2024年欧洲肿瘤内科学会(ESMO)年会于西班牙巴塞罗那正式召开，此次会议汇聚了全球肿瘤领域的前沿研究进展。四川科伦博泰生物医药股份有限公司(以下简称“科伦博泰”，6990.HK)核心产品TROP2 ...

This summary of recent health news includes U.S. Senator Bernie Sanders advocating for cheaper Ozempic, new findings on ...

Discover they major updates in oncology from the 2024 ESMO Congress, including featured breakthroughs from the leading ...